Eli Lilly Invests $5.3B to Boost Zepbound and Mounjaro Production
TL;DR
Eli Lilly is investing over $5 billion to expand manufacturing in Indiana for its popular weight loss and diabetes drugs, Zepbound and Mounjaro, due to high demand. This investment, the largest in the company's history, aims to produce the main ingredient, Tirzepatide, and is expected to create numerous high-wage jobs. The new site will start production in 2026, with full output by 2028, and is part of a broader initiative to boost local infrastructure and workforce development.
- Major boost for Zepbound and Mounjaro customers as manufacturer Eli Lily set to ramp up production of... The US Sun
- Mounjaro Shortage: Eli Lilly Invests $5.3 Billion For Production Forbes
- Eli Lilly adds $5.3 billion investment in Lebanon LEAP district FOX 59 Indianapolis
- Lilly invests further $5.3 bln in new Indiana site as obesity drug demand soars Reuters
- Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro The Associated Press
Want the full story? Read the original reporting
Read on The US Sun